Pharmaceutical company Endo International (Nasdaq:ENDP) (TSX:ENDP) reported on Tuesday the start of delivery of the US Food and Drug Administration approved mycophenolate mofetil hydrochloride (HCl) for injection.
This shipment is being initiated by the company's operating company, Par Pharmaceutical.
The mycophenolate mofetil hydrochloride (HCl) for injection is the generic version of Roche's CellCept and is the first and currently the only generic injectable available. CellCept is a registered trademark of Hoffman-LaRoche Inc.
For the 12 months ended 31 October 2016, the US sales of injectable CellCept were about USD42m, according to IMS Health data.
Mycophenolate mofetil hydrochloride (HCl) for injection is packaged in cartons of four 500 mg single dose vials.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream